Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. OMER
OMER logo

OMER Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Omeros Corp (OMER) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
10.280
1 Day change
6.64%
52 Week Range
17.650
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Omeros Corp (OMER) does not present a strong buy opportunity for a beginner investor with a long-term focus at this time. While hedge funds are significantly increasing their positions, technical indicators are neutral, and options data suggests mixed sentiment. Additionally, there are no strong positive catalysts or recent financial data to support a decisive buy recommendation.

Technical Analysis

The MACD is positive and expanding, indicating bullish momentum, but the RSI is neutral at 58.102, showing no clear overbought or oversold conditions. Moving averages are converging, suggesting indecision in the market. Key resistance is at 10.419, which is close to the current price, limiting immediate upside potential.

Options Data

Bullish
Open Interest Put-Call Ratio
Bearish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
6
Buy
7

Positive Catalysts

  • Hedge funds have significantly increased their buying activity by 185085.19% over the last quarter, indicating institutional interest.

Neutral/Negative Catalysts

  • Options data shows a high put-call volume ratio of 1.89, suggesting bearish sentiment. Additionally, the $5 strike put option saw significant volume, indicating expectations of potential downside. No significant insider activity or congress trading data is available.

Financial Performance

No financial data is available for the latest quarter, making it difficult to assess the company's growth trends or profitability.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst rating or price target changes are provided, leaving a gap in understanding Wall Street's sentiment toward the stock.

Wall Street analysts forecast OMER stock price to rise
4 Analyst Rating
Wall Street analysts forecast OMER stock price to rise
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 9.640
sliders
Low
36
Averages
43.67
High
55
Current: 9.640
sliders
Low
36
Averages
43.67
High
55
H.C. Wainwright
Brandon Folkes
maintain
$20 -> $40
AI Analysis
2026-01-08
Reason
H.C. Wainwright
Brandon Folkes
Price Target
$20 -> $40
AI Analysis
2026-01-08
maintain
Reason
H.C. Wainwright analyst Brandon Folkes raised the firm's price target on Omeros to $40 from $20 and keeps a Buy rating on the shares. The firm cites the approval of Yartemlea for hematopoietic stem cell transplant-associated thrombotic microangiopathy for the target boost. The analyst views the approval as a "critical inflection point" for Omeros.
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$20
2025-12-24
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$20
2025-12-24
maintain
Buy
Reason
H.C. Wainwright reiterated a Buy rating and $20 price target on Omeros following the FDA approval of Yartemlea for hematopoietic stem cell transplant-associated thrombotic microangiopathy. The firm sees the Yartemlea approval as a "significant validation" of Omeros value. H.C. Wainwright's current model assumed an 80% probability of success for Yartemlea in the U.S., and pricing of $150K per patient.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for OMER
Unlock Now

People Also Watch